Category: Antibody Drug

Ambrx and NovoCodex Biopharmaceuticals announced that they have formed a second collaboration to develop and commercialize Ambrx’s internally developed site-specific antibody drug conjugates. The antibody drug conjugates market is expected to grow at a CAGR of ~10% during the forecast period. What is the focus of the agreement: Under the agreement, Ambrx and NovoCodex will

With fourteen approved drugs and several drug candidates being evaluated under different stages of development, antibody drug conjugates (ADCs) are now recognized as a potent class of targeted therapeutics. The success of this relatively novel class of therapeutics is attributed to the ability of lead molecules to specifically identify and eliminate disease associated cells /

On 23 October 2023, Merck announced a development agreement for Daiichi Sankyo’s clinical-phase antibody-drug conjugate, namely patritumab deruxtecan (HER3-DXd), ifinatamab deruxtecan (I-DXd), and raludotatug deruxtecan (R-DXd), targeting cancer. Merck has invested $5.5 billion to jointly develop three of its candidate cancer drugs and is likely to invest up to $22 billion in addition depending on

Novel antibody therapies are chimeric proteins having antibodies attached lethal effector molecules. Currently, six of these therapies are commercially available, while around 140 molecules are under development majorly for oncological disorders. Multiple novel antibody formats have been engineered to enhance therapeutic efficacy. This has opened a new target space for the development of antibody therapeutics

Since the approval of Enbrel®, CD4 – Fc fusion protein (for the treatment of rheumatoid arthritis) in 1998, Fc fusion protein therapies have evolved into a prominent class of therapeutics. Currently, 13 Fc fusion protein based drugs are commercially available, while around 50 molecules are under development for various disease indications. Some of the Fc fusion

Antibody-drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have captured the attention of both large and small pharmaceutical companies, and academic / research institutions from all across the world. Fundamentally, these complex biotherapeutic entities demonstrate the combination of target specificity of an antibody and therapeutic features of a chemotherapy / cytotoxic

With close to 100 approved monoclonal antibodies, and over 550 molecules in the clinical pipeline, antibody based pharmacological interventions have become one of the fast growing segment of the biopharmaceutical industry. In fact, these interventions are anticipated to generate a cumulative sales of USD 300 billion by 2025. Further, within the antibody therapeutics industry, engineered

Over the years, various technological advancements, such as antibody engineering for site-specific conjugation and enhanced pharmacokinetic and pharmacodynamic properties, have paved the way for antibody drug conjugates to be recognized as potent therapies (ADC therapy) targeting a wide range of indications, including solid tumors and hematological malignancies. ADC therapy is an engineered therapy comprised of

Over time, several innovative technologies have been developed to support the designing and manufacturing of various types of antibody products; however, the aforementioned processes are characterized by high costs and technical complexities, especially during the production and downstream processing steps. Therefore, it is challenging for new entrants and companies with limited resources and capital, to

Antibody Drug Conjugates (ADCs) manufacturing known as the 21st Century Magic Bullets, have emerged as a promising class of targeted therapies being developed for the treatment of cancer. Two decades ago, in the year 2000, the domain witnessed the approval of first ADC known as Mylotarg®, by the US FDA.  This was followed by the

Antibody-Drug Conjugates (ADCs) have captured the attention of both large and small pharmaceutical companies, and academic / research institutions, engaged in the ADC contract manufacturing market. For the past few years, several failures of clinical trials were blamed for the lack of interest of some companies in this therapeutic approach. However, after a decade-long dribble

For more free insights, check out the detailed report ADC market insights report.

Global Antibody Drug Conjugates ADC market is expanding and is estimated to be around USD 7.72 billion in 2023. The compound annual growth rate of ADC market is estimated to be 9.50% in the coming decade. Roots Analysis has been publishing multiple articles and key insights pack for ADC market growing potential to keep the